CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
CANCER THERAPIES
IO SOLUTIONS PORTFOLIO
VIRTUAL EVENTS
LATEST EVIDENCE
Interventional Radiology / Interventional Oncology / Latest Evidence

 


Forging clinical partnerships investing in investigator-initiated research


We work with you and invest in research to provide the evidence you need to be confident in recommending proven interventional oncology strategies to your peers and your patients.


Clinical evidence with TheraSphere in liver cancer


For 20 years, we have been making significant investments in advancing clinical data for TheraSphere (Y90 SIRT treatment) building evidence of the benefits it offers and increasing our understanding of how to optimise personalised treatment strategies in the treatment of primary liver cancer (hepatocellular carcinoma and cholangiocarcinoma) and of mCRC (colorectal cancer that has metastasised to the liver). Beginning with more advanced stage patients to early-stage HCC with low tumour burden. From bridging and downstaging to lobectomy and segmentectomy, the versatility of TheraSphere has been proven in more than 50 publications, and more data is on its way….

 
EPOCH Trial
 

DOSISPHERE

Multi-centre, randomised phase II study: TheraSphere with standard vs personalised dosimetry in patients with advanced HCC.

Latest Evidence

LEGACY

Robust multicenter study confirming TheraSphere as a neoadjuvant or standalone therapy in treating unresectable solitary HCC.

Latest Evidence

TARGET

A global retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population.
Latest Evidence
 
Top